Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of therapies based upon tetracycline chemistry, has opened its expanded office in King of Prussia, PA. Located on First Avenue, the new space is designed to accommodate the company’s growing development, manufacturing, and commercial organizations.

“It’s an incredibly exciting time at Paratek as we get closer to potentially bringing our lead product candidate, omadacycline, to market,” said Evan Loh, president, chief operating officer, chief medical officer and director, Paratek. “Our expanded home in King of Prussia provides our growing team with the physical space and resources to fuel our continued commitment to bringing the very best in innovative antibiotic treatment options to patients to improve and potentially save lives.”

The renovated office space will initially house approximately 30 full-time employees, the majority of whom are focused on development and registration activities to support the potential New Drug Application to the U.S. Food and Drug Administration (FDA). At the appropriate time, Paratek plans to expand to bring in talented resources to provide for a successful launch of omadacycline, a novel broad spectrum once-daily oral and intravenous antibiotic being developed to treat serious community-acquired infections such as acute skin and skin structure infections and community-acquired bacterial pneumonia. Paratek anticipates adding as many as 65 employees in King of Prussia over the next 24 months as registration and pre-commercial activities ramp up prior to launch and has built the new office space to accommodate this projected rapid expansion.